West Pharmaceutical Services (WST) Other Accumulated Expenses (2009 - 2026)

West Pharmaceutical Services' Other Accumulated Expenses history runs 18 years deep, the most recent figure standing at $202.2 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 8.48% year-over-year to $202.2 million; the TTM figure through Mar 2026 stood at $202.2 million (up 8.48% YoY), while the FY2025 annual figure was $175.3 million, down 6.85% from the prior year.
• Other Accumulated Expenses came in at $202.2 million for Q1 2026 at West Pharmaceutical Services, up from $175.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $222.8 million in Q2 2025 to a low of $2.3 million in Q3 2022.
• A 5-year average of $156.4 million and a median of $169.0 million in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 97.98% in 2022 and jumped 6695.83% in 2023, its largest moves.
• West Pharmaceutical Services' Other Accumulated Expenses stood at $183.8 million in 2022, then fell by 15.56% to $155.2 million in 2023, then advanced by 21.26% to $188.2 million in 2024, then fell by 6.85% to $175.3 million in 2025, then rose by 15.35% to $202.2 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $202.2 million, $175.3 million, and $213.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison